
Emami Q1 FY27: consolidated revenue up 15% YoY, but PAT falls 15% on margin, tax swing
Emami's consolidated (primary basis) revenue rose 14.9% YoY to ₹1,039 Cr (+12.3% QoQ), but consolidated PAT fell 15.4% YoY to ₹138.9 Cr (-2.9% QoQ), missing our pre-result Street consensus (revenue ~₹1,055 Cr — roughly in line, -1.5%; EPS ~₹4.36 vs actual ₹3.15 — a clear miss). This is the first print to consolidate Axiom Ayurveda (from April 1) and IncNut Digital (60% stake, from June 1), so YoY comparisons are not fully like-for-like. The PAT decline is driven by two distinct effects. First, genuine operating margin compression: OPM fell to 21.8% from 23.7% YoY (though it expanded from 20.2% QoQ), and NPM fell to 13.1% from 17.7% YoY, on higher advertisement/promotion spend (₹203 Cr vs ₹180 Cr YoY) and employee costs (₹136 Cr vs ₹119 Cr YoY), alongside finance costs more than doubling YoY to ₹5.6 Cr on acquisition funding (₹100 Cr first tranche for Axiom's remaining 73.5% stake; ₹321 Cr for IncNut's 60% stake). Second, a tax-line swing: PBT before exceptional items actually rose 4.2% YoY to ₹194.7 Cr, but tax expense jumped to ₹55.8 Cr from ₹22.5 Cr as MAT credit accounting flipped from a ₹10.4 Cr benefit a year ago to a ₹13.5 Cr utilisation charge this quarter — a ~₹23.8 Cr negative swing that alone accounts for most of the increase in tax outgo. Stripping this MAT-line effect out, adjusted PAT is roughly flat YoY (-1.0%) rather than -15.4% reported, though the underlying operating-margin compression is real and independent of the tax effect. Management's prior (Q4 FY26) guidance flagged margin improvement via cost discipline and a 3% price hike, and double-digit summer-portfolio growth for FY27; this quarter's revenue growth is consistent with that confidence, but the YoY margin compression runs counter to the margin-improvement guidance — a miss on that specific commitment, at least for Q1. International business was guided to return to double-digit growth only from Q2 FY27, so its Q1 trajectory (not separately disclosed here) is not yet a test of that promise. Standalone (core Emami, ex-new subsidiaries) PAT was ₹182.2 Cr with EPS ₹4.17, and its PBT of ₹233.6 Cr grew against a stronger base — a cleaner read on the core business than the consolidated number, which is now diluted by two newly acquired, lower-margin/loss-making entities: IncNut's first stub period (June 1-30) contributed a ₹0.9 Cr net loss on ₹14.7 Cr revenue. No management press release commentary was available in the extracted materials to corroborate these drivers independently. Going into Q2 FY27, the two things to verify are whether the tax-line swing normalizes (this quarter's effective rate was 28.6% vs 12.1% a year ago) and whether international revenue delivers the double-digit growth management guided for from Q2 onward, alongside the first full quarter of IncNut/Axiom integration and their margin trajectory.
Key Highlights
- Consolidated revenue ₹1,039 Cr, +14.9% YoY / +12.3% QoQ — first quarter consolidating Axiom Ayurveda (from Apr 1) and IncNut Digital (60% stake, from Jun 1)
- Consolidated PAT ₹138.9 Cr, -15.4% YoY (-2.9% QoQ) despite PBT rising ~4.2% YoY to ₹194.7 Cr — gap driven by a MAT-credit swing from a ₹10.4 Cr benefit a year ago to a ₹13.5 Cr charge this quarter (adjusted PAT ~flat YoY)
- OPM compressed to 21.8% from 23.7% YoY (expanded from 20.2% QoQ); NPM fell to 13.1% from 17.7% YoY on higher A&P (₹203 Cr) and employee costs (₹136 Cr)
- Standalone PAT ₹182.2 Cr, EPS ₹4.17, PBT ₹233.6 Cr — core business read cleaner than consolidated, which is now diluted by new subsidiaries
- Finance costs more than doubled YoY to ₹5.6 Cr (consol) on acquisition funding: ₹100 Cr first tranche for Axiom, ₹321 Cr for IncNut's 60% stake
- IncNut's first stub period (Jun 1-30): revenue ₹14.7 Cr, net loss ₹0.9 Cr — immaterial to the print but the first data point on the D2C bet
- EPS (basic) ₹3.15 consolidated vs ₹3.76 year-ago; missed pre-result Street EPS consensus of ~₹4.36 though revenue was roughly in line with ~₹1,055 Cr estimate
Price Impact
More from EMAMILTD